Autologous Chondrocyte Implantation — two-stage, cell-culture-based repair of focal chondral defects, from biopsy to hyaline-like cartilage
Autologous Chondrocyte Implantation begins with a minimally invasive arthroscopic biopsy that removes a small full-thickness sliver of the patient's own articular cartilage. Because the graft population must expand into millions of cells over the following weeks, both the harvest site and the patient must be chosen carefully: the tissue has to be genuinely healthy, and the joint has to be a good long-term candidate for a durable, cell-based repair.
ACI/MACI is not a treatment for generalized osteoarthritis — it is designed for a specific clinical picture: a focal, contained chondral or osteochondral defect surrounded by healthy cartilage and an intact subchondral bone bed.
Favorable candidate profile: • Younger, physiologically active patients (typically under ~50 years) with higher intrinsic chondrocyte proliferative capacity • Single or limited focal defects, generally 2–10 cm² in area — the size range where cell-based repair has the clearest evidence advantage • Contained lesion with stable, vertical cartilage walls and healthy surrounding ("shoulder") cartilage that can support graft-host integration • Intact or reconstructable subchondral bone — bone loss or cystic change usually requires staged bone grafting first • Normal knee alignment and stable ligaments, or these are corrected concurrently (osteotomy, ligament reconstruction) — an unstable or malaligned joint will overload and fail any cartilage repair
Poor candidates include patients with diffuse osteoarthritis, inflammatory arthropathy, uncorrected malalignment, or advanced age with reduced chondrocyte yield and proliferative potential. Because the entire pipeline takes months and two surgeries, patient selection has an outsized effect on whether the eventual repair tissue will actually mature into a durable, hyaline-like surface.
The biopsy is performed as a brief, standalone arthroscopic procedure (or combined with the diagnostic arthroscopy that first identifies and measures the defect).
• A small full-thickness cartilage strip (roughly 200–300mg, about the size of two rice grains laid end to end) is sharply excised down to — but not through — the subchondral bone plate • Harvest site is deliberately chosen from a minimally weight-bearing region: the superior medial or lateral margin of the femoral condyle, or the intercondylar notch edge, where donor-site cartilage loss has negligible long-term functional consequence • The defect itself is inspected, probed, and measured at this same procedure — its size, depth, containment, and the quality of the surrounding cartilage shoulder all inform surgical planning for the second-stage implantation • The biopsy specimen is placed in sterile transport medium and shipped, under controlled chain-of-custody, to a certified cell-processing laboratory within 24–48 hours
A reasonable concern with any autograft procedure is that the harvest itself creates a new problem. For cartilage biopsy, the risk is deliberately engineered to be small: the harvested strip is tiny relative to total joint cartilage surface area, and it is taken from a site that bears essentially no load during normal gait or activity. Long-term follow-up of biopsy donor sites shows no measurable functional deficit — the tradeoff of a small, asymptomatic donor defect for a full expandable chondrocyte population is central to what makes ACI/MACI viable as a two-stage procedure.
The biopsy sample is transported to a cell-processing facility, enzymatically digested to release individual chondrocytes, and then expanded in monolayer culture over roughly three to five weeks. The central technical challenge of this stage is not simply generating enough cells — it is preserving the chondrocytic phenotype while doing so, because monolayer expansion actively pushes cells away from the very identity that makes them useful.
The biopsy tissue is minced and digested with proteolytic enzymes — typically collagenase, sometimes preceded by pronase or hyaluronidase pretreatment — to break down the dense extracellular matrix (predominantly type II collagen and aggrecan) that normally encases and immobilizes chondrocytes within cartilage.
This digestion liberates individual, viable chondrocytes from a matrix that is, by design, extremely resistant to enzymatic and mechanical disruption — cartilage matrix must withstand decades of joint loading, so isolating living cells from it without killing them requires carefully titrated digestion time, enzyme concentration, and temperature. The isolated cell suspension is filtered, counted, and assessed for viability before being seeded into culture flasks.
Isolated chondrocytes are seeded at low density onto standard tissue-culture plastic and expanded across successive passages, each time being enzymatically detached, counted, and re-seeded at a larger surface area:
• Passage 0 (P0): primary culture directly from the digested biopsy — lowest cell number, highest phenotypic fidelity • Passage 1–2 (P1–P2): cells proliferate rapidly on flat plastic in growth-factor-supplemented medium; population doubles roughly every 2–4 days under optimal conditions • By 3–5 weeks: the population has typically expanded on the order of 10,000-fold from the original biopsy, yielding tens of millions of cells — enough to seed a construct at roughly one million cells per square centimeter of defect area, the density generally targeted for adequate matrix-forming capacity after implantation
Cell counts, viability, and sterility are checked at each passage, and the expanded population is cryopreserved or shipped fresh to the surgical center once target numbers are reached.
Chondrocytes are not naturally adapted to grow on flat, rigid, two-dimensional plastic. In their native environment they are round, non-motile cells embedded in a soft, avascular, three-dimensional matrix. When forced into monolayer expansion, chondrocytes progressively "dedifferentiate": they flatten, become spindle-shaped and migratory, and shift their gene expression program toward a fibroblast-like state.
Molecularly, this shows up as declining expression of the chondrocyte markers type II collagen (COL2A1), aggrecan, and SOX9, alongside rising expression of type I collagen — the matrix protein characteristic of fibrous, mechanically inferior scar-like tissue rather than hyaline cartilage. The longer and more extensively cells are passaged, the more complete this drift becomes.
This creates a direct tension: more passages mean more cells (better surgical dose, easier logistics), but more passages also mean a more fibroblastic, less chondrogenic cell population at the moment of implantation. Cell manufacturers manage this trade-off by limiting expansion to a small number of passages (commonly two to three), using chondrogenic growth-factor supplementation (e.g., TGF-β, FGF-2 combinations) to slow the drift, and — for scaffold-based generations — allowing a period of three-dimensional culture on the scaffold itself, which can partially redifferentiate cells back toward a rounder, more matrix-productive phenotype before the construct is implanted.
The technique for getting expanded chondrocytes back into the joint has gone through three distinct generations since ACI was first described in 1994. Each generation solved a problem introduced by the last — periosteal hypertrophy, technical complexity of open suturing, uneven cell distribution — culminating in matrix-induced/matrix-associated ACI (MACI), now the dominant standard of care.
The original technique (Brittberg et al., 1994) injected a suspension of expanded chondrocytes directly into the debrided defect, then sutured a flap of the patient's own periosteum (harvested from the proximal tibia) over the top to seal the cells in place.
This was a genuine breakthrough — the first clinically successful cell-based cartilage repair — but it carried real technical burdens: it required an open arthrotomy (a formal joint-opening incision) for both harvesting the periosteal flap and precisely suturing it watertight over an often irregularly-shaped defect, and the graft depended on the surgeon's suturing skill to prevent cell leakage.
Its most troublesome complication was periosteal hypertrophy — overgrowth of the periosteal patch itself, sometimes requiring a separate arthroscopic shaving procedure — occurring in a substantial minority of cases (historically cited around 20–25%) and representing the leading cause of reoperation after first-generation ACI.
To reduce periosteal hypertrophy, surgeons substituted a porous type I/III collagen membrane for the autologous periosteal flap as the covering layer sutured or glued over the injected cell suspension. This eliminated the second donor-site harvest (no tibial periosteum needed) and substantially reduced the hypertrophy complication, since the collagen membrane does not have the same overgrowth potential as living periosteal tissue.
Cell delivery itself was largely unchanged — a liquid chondrocyte suspension was still injected beneath the membrane — so this generation is best understood as an incremental fix to the covering material rather than a change in how cells were delivered to the defect.
MACI represents the more fundamental shift: instead of injecting a free cell suspension into the defect and covering it afterward, expanded chondrocytes are seeded directly onto a collagen bilayer scaffold ex vivo, in the laboratory, days before the implantation surgery. The scaffold — typically a porous type I/III collagen membrane with a dense smooth outer surface and a porous cell-adherent inner surface — arrives at the operating room as a pre-formed, cell-populated patch, cut to the size and shape of the defect and fixed in place with fibrin glue, generally without the extensive suturing required by earlier generations.
Advantages that made MACI the current standard of care: • Technically simpler and faster implantation, often achievable through an arthroscopic-assisted or mini-arthrotomy approach rather than a full open arthrotomy • More even, reproducible cell distribution across the defect (cells are already homogeneously seeded on the scaffold rather than pooling within an injected liquid suspension) • Substantially reduced hypertrophy and graft delamination complications relative to periosteal-flap techniques • Fibrin-glue-only fixation reduces operative time and technical demand compared to circumferential suturing
Roughly three to five weeks after the original biopsy — once the expanded (and, for MACI, scaffold-seeded) cell population is ready — the patient returns for a second, more consequential surgery: the cultured cells are permanently implanted into the prepared defect. This step determines whether the graft will actually integrate with host tissue, and meticulous defect preparation matters as much as the cell biology itself.
The defect is re-exposed (arthroscopically for MACI, generally via arthrotomy for earlier generations) and meticulously debrided: all remaining damaged or fibrillated cartilage is removed down to a clean, stable rim of healthy surrounding cartilage with vertical (not shelved or undermined) walls.
A critical, generation-independent step is removal of the calcified cartilage layer at the base of the defect while preserving the underlying subchondral bone plate intact — leaving calcified cartilage behind can block matrix integration, while over-aggressive removal that breaches the subchondral bone can cause bleeding into the defect, fibrin clot formation, and a shift toward fibrocartilage-type healing rather than the intended hyaline-like outcome.
Defect size and shape are precisely measured (often with a sterile foil or paper template) so the implant — whether an injected volume bounded by a cut membrane, or a pre-formed MACI scaffold — can be matched to the defect geometry.
For MACI, the cell-seeded scaffold is trimmed from the sized template directly to the defect's exact contour and gently press-fit into place, cell-side down, so that the porous, chondrocyte-populated surface directly contacts the debrided defect floor and can integrate with host tissue and bone marrow elements at the base.
For earlier-generation ACI, the periosteal or collagen membrane cover is first sutured (or glued) around most of the defect perimeter, leaving a small opening through which the liquid chondrocyte suspension is injected beneath the membrane, after which the opening is sealed.
In all generations, care is taken to avoid overfilling (which can cause the graft to protrude above the surrounding cartilage surface and abrade against the opposing joint surface) or underfilling (which leaves a step-off that concentrates mechanical stress at the graft-host interface).
The construct is secured with fibrin glue applied circumferentially at the graft-host interface, frequently reinforced with fine sutures anchoring the membrane or scaffold edge to the surrounding cartilage rim, particularly for larger or more irregularly-shaped defects.
Before closure, surgeons commonly test the repair with gentle range-of-motion cycling and a saline (sometimes dye-assisted) leak test to confirm a watertight seal and that the graft does not displace under simulated joint motion.
Why defect preparation technique matters so much: unlike a scaffold sitting inertly in a dish, the implanted construct must achieve biological integration with living host cartilage and bone at its margins and base — new matrix has to bridge seamlessly from graft to host tissue for the repair to function as a continuous, load-bearing surface rather than a patch that eventually delaminates. Meticulous, methodical defect preparation is therefore one of the strongest technique-dependent predictors of long-term graft survival.
Implantation is not the end of the process — it is the start of a months-long biological remodeling phase. Over roughly six to twelve months, chondrocytes within the graft gradually synthesize a cartilage-like extracellular matrix rich in type II collagen and proteoglycans, producing repair tissue that more closely resembles native hyaline cartilage than the fibrocartilage typically produced by marrow-stimulation techniques like microfracture — though it is usually still not histologically identical to untouched native hyaline cartilage, hence the common description "hyaline-like."
Immediately after implantation, the graft is a relatively immature, cell-dense construct with limited structural matrix. Over the following months, seeded chondrocytes — ideally still expressing a chondrogenic gene program despite their monolayer expansion history — progressively secrete and organize a new extracellular matrix dominated by type II collagen fibrils and aggrecan-based proteoglycans, the two molecular signatures that give native hyaline cartilage its combination of tensile resilience and compressive, load-bearing stiffness.
This is a slow, biologically driven process rather than a mechanical healing event: matrix deposition, collagen fibril cross-linking and organization, and the graft's transition from a soft, cell-rich tissue to a firmer, more mechanically competent one unfolds over roughly six to twelve months, and full biomechanical maturation can continue even longer. Serial MRI and, where available, second-look arthroscopic biopsy generally show progressively improving fill and signal characteristics over this period, though the resulting tissue is more accurately described as hyaline-like rather than a perfect histological match to untouched native cartilage.
Microfracture (marrow-stimulation) works by drilling small holes into the subchondral bone, releasing marrow elements and mesenchymal stem cells that form a fibrin clot which matures predominantly into fibrocartilage — a repair tissue dominated by type I collagen, mechanically inferior to native hyaline cartilage in both stiffness and long-term wear resistance.
ACI/MACI, by contrast, delivers a large population of committed chondrocytes directly, producing matrix that is comparatively richer in type II collagen. This distinction becomes clinically important with time and defect size: multiple longer-term comparative studies and registry follow-ups (5-to-10-plus years) have found that ACI/MACI repairs tend to show better durability and lower rates of clinical failure than microfracture, with the gap most pronounced for larger defects (roughly >4 cm²), where fibrocartilage from microfracture is especially prone to early deterioration under repetitive load.
The biological maturation timeline of a cell-based graft has a direct practical consequence: rehabilitation after ACI/MACI is deliberately slower and more conservative than after microfracture. Because the graft is a living, immature tissue that needs a protected mechanical environment to mature properly, postoperative protocols typically involve an extended period of restricted or partial weight-bearing (often several weeks of toe-touch or protected loading, sometimes with continuous passive motion), a gradual, staged progression through range-of-motion and strengthening phases, and a return to full sport or high-demand activity that is commonly not cleared until roughly nine to twelve months post-implantation — longer than the return-to-activity timelines typically associated with microfracture.
This represents the central tradeoff of cell-based cartilage repair: patients and surgeons accept a longer, more disciplined rehabilitation course in exchange for repair tissue that is more durable over the years that follow, particularly for larger or more demanding defects where that durability advantage matters most.